Professor | Group Leader+617 3362 0415
Professor Andreas Suhrbier did his first post-doc at Imperial College of Science and Technology, London, UK (1986-1989) working on the liver stage of malaria. He came to Australia in 1990 on a Royal Society Fellowship and Wellcome Trust Advanced Training Fellowship in Tropical Medicine. From 1992−2000, he was appointed as a lecturer at the Australian Centre for International & Tropical Health & Nutrition. During 1994−2003, Professor Suhrbier was a program and project leader, member of the Scientific Advisory Committee and Research and/or Development Advisory Committee of the Co-operative Research Center for Vaccine Technology.
In 2000, he became a Group Leader and now leads the Inflammation Biology Group at QIMR Berghofer. Since 2004, Professor Suhrbier has been a Research Fellow with the National Health and Medical Research Council (NHMRC) of Australia and in 2019, he was awarded an Investigator grant from the NHMRC (Impact option: 100% Economic).
Professor Suhrbier is an inventor on 18 awarded international patents: 13 have been commercialised, 11 led to human clinical trials, one covers ISCOM vaccines, five support Picato (http://bit.ly/39mUWhK). During his career, he has been a consultant for Sementis, Valneva, Abivax, Leo Pharma, GSK, Paradigm, WHO, Aventis Pasteur, CSL, Bavarian Nordic, Peplin and C-Bio.
The Inflammation Biology Group has developed, refined and characterised a number of mouse models used to gain new insights into the factors that regulate viral infection and inflammatory disease. The models are also exploited for collaborative R&D with industry to test potential new interventions (e.g. vaccines, anti-inflammatory drugs, anti-viral agents).
The group has over 25 years of activity in improving our understanding of the immunopathogenesis of the diseases cause by arthritogenic alphaviruses such as chikungunya virus and Ross River virus. We have also developed mouse models of Zika virus (foetal brain infection and testes damage) and Yellow fever virus liver pathology, which have been used in the development of vaccines and characterisation of pathogenic determinants.
Very recently, we repurposed a PC3 laboratory and have started to undertake research into SARS-CoV-2 and COVID-19 using transgenic hACE2 mice.
2011-2019: Scientific Advisory Board, Sementis Pty Ltd (Australia)
2014: Named on the 2014 NHMRC External Project Grant Assessor Outstanding Contribution Honour Roll
2010: Eureka Award Finalist. Category: Medical Research Translation (The Industry & Investment NSW Jamie Callachor Eureka Prize). A new anti-cancer drug from radium weed. Aylward, Suhrbier, Parsons, Cozzi, Ogbourne
1982-1985: PhD received 31 January 1986. Title: The conservation and formation of desmosomes, PhD Supervisor: Dr DR Garrod. CRC Medical Oncology Unit, Southampton General Hospital Southampton Hants UK
1978-1982: BA Biochemistry (Honours). New College, University of Oxford: Open Scholar (awarded to top 5% of accepted students after entrance exam)